We thank the participants of the study.

Funding

The study sponsor, Teva Branded Pharmaceutical Products R&D, Inc., funded this study and the Rapid Service and Open Access Fees for this manuscript.

Medical Writing and/or Editorial Assistance

Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Jeffrey A. Blair, PhD, and Jennifer C. Jaworski, MS, BCMAS, and editing support by Kelsey Hogan, MS, all of Ashfield MedComms, an Inizio Company, and funded by Teva Branded Pharmaceutical Products R&D, Inc.

Author Contributions

Participated in concept and design of the work: Mark Suett, Amanda Wilhelm, Nayla Chaijale, Kelli R. Franzenburg, Sanjay Gandhi, and Marko Mychaskiw. Participated in the acquisition and analysis of the work: Blaine Cloud. Participated in the interpretation of data for the work: Delbert G. Robinson, Mark Suett, Amanda Wilhelm, Nayla Chaijale, Kelli R. Franzenburg, Sanjay Gandhi, and Marko Mychaskiw. Participated in drafting and/or critical revision and approval of the final manuscript: Delbert G. Robinson, Mark Suett, Amanda Wilhelm, Nayla Chaijale, Kelli R. Franzenburg, Sanjay Gandhi, Blaine Cloud, and Marko Mychaskiw.

Prior Presentation

This data has been previously presented at Robinson DG, Suett M, Chaijale N, et al. Patient and healthcare professional preferences and treatment experiences with TV-46000, a long-acting subcutaneous antipsychotic risperidone formulation. Presented at: 6th Annual Psych Congress Elevate; June 3–5, 2022; Las Vegas, Nevada. Robinson DG, Suett M, Wilhelm A, et al. Patient and healthcare professional preferences and treatment experiences with TV-46000, a long-acting subcutaneous antipsychotic (LASCA) risperidone formulation. Presented at: 4th Annual Congress of the Schizophrenia International Research Society; April 6–10, 2022; Florence, Italy. Robinson DG, Suett M, Wilhelm A, et al. Patient and healthcare professional preferences and treatment experiences with TV-46000, a long-acting subcutaneous antipsychotic (LASCA) risperidone formulation. Presented at: 25th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists; April 24–27, 2022; San Antonio, Texas. Robinson D, Suett M, Wilhelm A, et al. Patient preferences and treatment experiences with TV-46000, a long-acting subcutaneous antipsychotic agent. Presented at: 27th Annual National Psychopharmacology Update; February 16–19, 2022; Las Vegas, Nevada. Robinson DG, Suett M, Wilhelm A, et al. Patient preferences and treatment experiences with TV-46000, a long-acting subcutaneous injectable risperidone formulation. Presented at: 34th Annual Psych Congress; October 29–November 1, 2021; San Antonio, Texas. Robinson D, Suett M, Wilhelm A, et al. Healthcare professional preferences and treatment experiences with TV-46000, a long-acting injectable risperidone formulation. Presented at: 27th Annual National Psychopharmacology update; February 16–19, 2022; Las Vegas, Nevada. Robinson DG, Suett M, Wilhelm A, et al. Healthcare professional preferences and treatment experiences with TV-46000, a long-acting injectable risperidone formulation. Presented at: 34th Annual Psych Congress; October 29–November 1, 2021; San Antonio, Texas. Robinson DG, Suett M, Wilhelm A, et al. Patient and healthcare professional preferences and treatment experiences with TV-46000, a long-acting subcutaneous antipsychotic risperidone formulation. Presented at: 6th Annual Meeting of the American Psychiatric Nurses Association; October 19–22, 2022; Long Beach, California. Robinson DG, Suett M, Wilhelm A, et al. Nurse preferences and treatment experiences with TV-4 6000, a long-acting subcutaneous antipsychotic (LASCA) agent. Presented at: 6th Annual Meeting of the American Psychiatric Nurses Association; October 19–22, 2022; Long Beach, California.

Disclosures

Delbert G. Robinson has been a consultant for/has received honoraria from Teva Pharmaceuticals. He has also been a consultant to Advocates for Human Potential, American Psychiatric Association, C4 Innovations, Costello Medical Consulting, Health Analytics, Innovative Science Solutions, Janssen, Lundbeck, Neurocrine, Neuronix, Otsuka, and US WorldMeds and has received grant support from Otsuka. Mark Suett, Nayla Chaijale, Kelli R. Franzenburg, Sanjay Gandhi, and Marko Mychaskiw are employees and shareholders of Teva Pharmaceuticals. Amanda Wilhelm was an employee of Teva Pharmaceuticals at the time of this research. Blaine Cloud was an employee of Clinical SCORE at the time of this research; Clinical SCORE received payments from Teva Pharmaceuticals in relation to this study. Amanda Wilhelm was in Teva Branded Pharmaceutical Products R&D, Inc., North America Medical Affairs at the time of this research. Blaine Cloud was in Clinical SCORE at the time of this research.

Compliance with Ethics Guidelines

Materials including the survey, electronic informed consent form, and all patient-facing recruitment materials were approved by a central IRB, Advarra (Pro00044509). All participants were aware of the objectives of the study and that the results of the study would be published. Patients and clinical trial staff participating provided electronic informed consent before survey administration. Patients were only included if they were competent to provide consent. Individuals’ data was protected by remaining with the clinical site, ensuring HIPAA compliance, and information provided to third-party organizations did not contain identifiable patient information and was encrypted and stored on a password-protected secure server. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.

Data Availability

The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Qualified researchers may request access to patient level data and related study documents, including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified, and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.